Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JODY TVERSKY

Allopathic & Osteopathic Physicians Allergy & Immunology Allergy

NPI
1619014263
CMS profile
523023
Location
BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$18,376.15

26 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $15,417.44 20
Amgen Inc. $2,623.41 3
GENZYME CORPORATION $126.80 1
ADMA BioManufacturing LLC $109.26 1
Grifols USA, LLC $99.24 1

Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JODY TVERSKY

NPI 1619014263 · CMS profile ID 523023

Allopathic & Osteopathic Physicians / Allergy & Immunology / Allergy

BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619014263?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JODY TVERSKY, NPI 1619014263, CMS profile ID 523023. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619014263?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JODY TVERSKY, NPI 1619014263, CMS profile ID 523023. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619014263?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JODY TVERSKY, NPI 1619014263, CMS profile ID 523023, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1619014263?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

26 matching records · $18,376.15 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 26 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–26 of 26.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Grifols USA, LLC $99.2412/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011888651 CMS
AstraZeneca Pharmaceuticals LP $950.0011/29/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015238431 CMS
Amgen Inc. $188.2611/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019967131 CMS
Amgen Inc. $85.1511/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019967133 CMS
Amgen Inc. $2,350.0010/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019967135 CMS
AstraZeneca Pharmaceuticals LP $2,350.0010/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014440919 CMS
AstraZeneca Pharmaceuticals LP $188.2610/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011805453 CMS
AstraZeneca Pharmaceuticals LP $85.1510/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014574815 CMS
AstraZeneca Pharmaceuticals LP $15.4810/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015274032 CMS
AstraZeneca Pharmaceuticals LP $3,700.0008/07/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015893773 CMS
AstraZeneca Pharmaceuticals LP $89.1008/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011408351 CMS
AstraZeneca Pharmaceuticals LP $250.0008/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015678189 CMS
AstraZeneca Pharmaceuticals LP $2,350.0005/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016221279 CMS
AstraZeneca Pharmaceuticals LP $13.7105/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011747787 CMS
AstraZeneca Pharmaceuticals LP $52.4005/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012091917 CMS
GENZYME CORPORATION $126.8003/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050480819 CMS
ADMA BioManufacturing LLC $109.2603/10/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058971583 CMS
AstraZeneca Pharmaceuticals LP $1,850.0003/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014831313 CMS
AstraZeneca Pharmaceuticals LP $110.0003/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015409581 CMS
AstraZeneca Pharmaceuticals LP $116.4702/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016191017 CMS
AstraZeneca Pharmaceuticals LP $100.2202/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011272519 CMS
AstraZeneca Pharmaceuticals LP $5.1502/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015668437 CMS
AstraZeneca Pharmaceuticals LP $2,800.0002/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016052569 CMS
AstraZeneca Pharmaceuticals LP $250.0001/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015222317 CMS
AstraZeneca Pharmaceuticals LP $78.7501/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011594703 CMS
AstraZeneca Pharmaceuticals LP $62.7501/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011805217 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $25,291.41 34
PY2020 $2,945.73 5
PY2021 $26,247.79 28
PY2022 $45,282.45 54
PY2023 $18,376.15 26
PY2024 $32,918.59 45
PY2025 $24,194.70 26

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $469,828.62 11
PY2024 Principal investigator $252,344.50 16
PY2023 Principal investigator $421,869.07 29
PY2022 Recipient $750.00 2
PY2022 Principal investigator $278,892.10 6
PY2021 Principal investigator $345,046.90 6
PY2020 Principal investigator $209,131.42 5
PY2019 Principal investigator $254,534.83 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,439.76 12/31/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyposis WAYPOINT No dispute reported 06/30/2026 991131025
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $786.31 11/28/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977200457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $907.18 10/09/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977187245
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $786.31 10/09/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977187251
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $786.31 10/09/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977187257
Principal investigator 1 Celgene Corporation $3,722.00 10/06/2023 Non-covered Recipient Entity
Johns Hopkins University School Of Medicine
Phase III CC-93538 Treat-Through (CC-93538-EE-001) Wk24 PE Primary - A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolesc No dispute reported 06/30/2026 1026489595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,277.15 09/07/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977181621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,139.67 09/07/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977181627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,277.15 09/07/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977181635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,139.67 09/07/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977181639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,139.67 09/07/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977181647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,139.67 09/07/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977181653
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,277.15 09/07/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977181659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,139.67 09/07/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977181665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,277.15 09/07/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977181671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,277.15 09/07/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977181677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $786.31 09/07/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977181683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $786.31 09/07/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977181689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $95,078.01 07/11/2023 Non-covered Recipient Entity
JHU SCHOOL OF MEDICINE
EFFICACY OF DUPILUMAB FOR PATIENTS WITH CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS (CRSSNP): A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE II STUDY No dispute reported 06/30/2026 977163601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,350.00 06/30/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY DIVISION OF INFECTIOUS DISEASES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977152267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,608.00 06/30/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY DIVISION OF INFECTIOUS DISEASES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977152277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,015.00 06/30/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY DIVISION OF INFECTIOUS DISEASES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977152289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,020.00 06/30/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY DIVISION OF INFECTIOUS DISEASES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977152299
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,000.00 06/30/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY DIVISION OF INFECTIOUS DISEASES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977152311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $63,385.34 05/16/2023 Non-covered Recipient Entity
JHU SCHOOL OF MEDICINE
EFFICACY OF DUPILUMAB FOR PATIENTS WITH CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS (CRSSNP): A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE II STUDY No dispute reported 06/30/2026 977109461
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31,692.67 05/16/2023 Non-covered Recipient Entity
JHU SCHOOL OF MEDICINE
EFFICACY OF DUPILUMAB FOR PATIENTS WITH CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS (CRSSNP): A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE II STUDY No dispute reported 06/30/2026 977109465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $95,078.01 05/16/2023 Non-covered Recipient Entity
JHU SCHOOL OF MEDICINE
EFFICACY OF DUPILUMAB FOR PATIENTS WITH CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS (CRSSNP): A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE II STUDY No dispute reported 06/30/2026 977109471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $63,385.34 05/09/2023 Non-covered Recipient Entity
JHU SCHOOL OF MEDICINE
EFFICACY OF DUPILUMAB FOR PATIENTS WITH CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS (CRSSNP): A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE II STUDY No dispute reported 06/30/2026 977107373
Principal investigator 1 AstraZeneca Pharmaceuticals LP $24,172.11 01/31/2023 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyposis WAYPOINT No dispute reported 06/30/2026 991134171